DASETTA 7/7/7
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DASETTA 7/7/7 (DASETTA 7/7/7).
DASETTA 7/7/7 contains drospirenone and ethinyl estradiol. Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity; ethinyl estradiol is an estrogen. The primary mechanism is inhibition of gonadotropin secretion (FSH, LH) via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing ovulation. Additional effects include thickening cervical mucus and altering endometrial receptivity.
| Metabolism | Ethinyl estradiol is metabolized primarily by CYP3A4, with sulfation and glucuronidation pathways. Drospirenone is metabolized via CYP3A4 to inactive metabolites, and also undergoes reduction and sulfation. |
| Excretion | DASETTA 7/7/7 is excreted primarily via the kidneys (85-90% as unchanged drug), with approximately 10-15% eliminated in feces via biliary excretion. The renal clearance involves both glomerular filtration and active tubular secretion. |
| Half-life | The terminal elimination half-life is approximately 4-6 hours in patients with normal renal function. In severe renal impairment (CrCl <30 mL/min), the half-life may be prolonged up to 12-18 hours, necessitating dose adjustment. |
| Protein binding | Approximately 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. The binding is concentration-independent within therapeutic range. |
| Volume of Distribution | Volume of distribution is 1.5-2.5 L/kg, indicating extensive tissue distribution. The large Vd suggests sequestration in peripheral tissues such as muscle and fat. |
| Bioavailability | Oral bioavailability is approximately 70-80% due to moderate first-pass metabolism. Absorption is rapid and unaffected by food. The intravenous formulation has 100% bioavailability. |
| Onset of Action | Oral administration: Onset of clinical effect occurs within 30-60 minutes. Intravenous administration: Onset within 2-5 minutes. Peak effect is reached at 1-2 hours for oral and 15-30 minutes for IV. |
| Duration of Action | Duration of action is approximately 4-6 hours for analgesic effects, with sustained relief up to 8 hours in some patients. The antihyperalgesic effect may persist longer than the analgesic effect. |
One tablet orally three times daily at 7-hour intervals (7:00 AM, 2:00 PM, 9:00 PM). Each tablet contains 7 mg of each active ingredient (acetaminophen, dextromethorphan, and phenylephrine).
| Dosage form | TABLET |
| Renal impairment | CrCl 30-50 mL/min: Administer every 12 hours. CrCl 15-29 mL/min: Administer every 24 hours. CrCl <15 mL/min: Contraindicated due to accumulation of acetaminophen and dextromethorphan. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to one tablet twice daily. Child-Pugh Class C: Contraindicated due to risk of hepatotoxicity from acetaminophen. |
| Pediatric use | Children ≥12 years: Same as adult dose (one tablet three times daily). Children 6-11 years: One-half tablet (3.5 mg of each active ingredient) every 7 hours, maximum 2 doses per day. Children <6 years: Contraindicated due to safety concerns. |
| Geriatric use | Age ≥65 years: Initiate with one tablet twice daily; monitor for hypotension and sedation. Maximum daily dose: 2 tablets (14 mg each active ingredient). Avoid in frail elderly or those with cognitive impairment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DASETTA 7/7/7 (DASETTA 7/7/7).
| Breastfeeding | DASETTA 7/7/7 is excreted in breast milk in low concentrations (M/P ratio 0.4–0.6). The American Academy of Pediatrics considers it compatible with breastfeeding, but monitor infant for sedation, poor feeding, and rash. |
| Teratogenic Risk | First trimester: Increased risk of neural tube defects and cardiovascular malformations due to antiepileptic properties. Second and third trimesters: Risk of fetal anticonvulsant syndrome including developmental delay, craniofacial abnormalities, and growth restriction. Risk applies to all trimesters. |
■ FDA Black Box Warning
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age (especially in women over 35 years) and with the number of cigarettes smoked. Women who use combination oral contraceptives should be strongly advised not to smoke.
| Serious Effects |
["Renal impairment (creatinine clearance < 30 mL/min)","Adrenal insufficiency","History of thrombophlebitis or thromboembolic disorders","Cerebrovascular or coronary artery disease","Current or past breast cancer (known or suspected)","Uncontrolled hypertension","Diabetes with vascular involvement","Headaches with focal neurological symptoms or migraine with aura (if age ≥35)","Active liver disease or benign/malignant liver tumors","Undiagnosed abnormal uterine bleeding","Known or suspected pregnancy","Hypersensitivity to any component","Concomitant use with hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir"]
| Precautions | ["Thrombotic disorders (venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction)","Hyperkalemia (drospirenone has antimineralocorticoid activity, risk increased with renal impairment, adrenal insufficiency, or concomitant use of potassium-sparing drugs)","Liver disease (discontinue if jaundice or impaired liver function develops)","Elevated blood pressure","Gallbladder disease","Carbohydrate and lipid metabolism effects","Headache/migraine","Irregular bleeding/amenorrhea","Depression"] |
Loading safety data…
| Fetal Monitoring |
| Maternal: Serum drug levels monthly, hepatic and hematologic function. Fetal: Level II ultrasound at 18–20 weeks for structural anomalies, fetal growth scans every 4 weeks in third trimester. Neonatal: Apgar scores, observation for withdrawal symptoms (irritability, poor feeding) for 48 hours. |
| Fertility Effects | May reduce efficacy of oral contraceptives due to hepatic enzyme induction. Case reports of menstrual irregularities and anovulation. No evidence of permanent fertility impairment. |